Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-03-18 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
华创证券有限责任公司关于公司2021年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by 华创证券 regarding the 2021年度募集资金存放与使用情况 (2021 annual fundraising capital deposit and usage) of 云南沃森生物技术股份有限公司. It references regulatory guidelines related to fundraising capital management and usage, details the amounts raised, usage, and storage of funds, and includes an independent financial advisor's verification opinion. The document is a focused audit on the use and storage of raised funds, not a full annual report or earnings release. It contains detailed financial and compliance information related to fundraising capital, consistent with an Audit Report / Information filing. The length (7928 characters) and content indicate it is the report itself, not just an announcement. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2021
2022-03-18 Chinese
关于控股子公司上海泽润生物科技有限公司对其全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about a capital increase (增资) by its controlling subsidiary to its wholly owned subsidiary. It details the amount of capital increase, the purpose, the financial status of the involved companies, and the impact of the capital increase. There are no financial statements or comprehensive financial reports included, only a description of the capital injection event. The document length is 2617 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising or capital structure changes.
2022-03-18 Chinese
关于回购公司股份方案的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the company's plan to repurchase its own shares. It includes specifics about the purpose, conditions, price limits, quantities, funding sources, implementation period, and the impact on the company's share structure. It also contains risk disclosures, management analysis, independent directors' opinions, and legal compliance statements. The document is not a financial report, earnings release, or management discussion but a formal announcement of a share repurchase program. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares. The document length is substantial and contains detailed information about the repurchase plan, not just a brief notice or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2022-03-18 Chinese
关于购买董监高责任保险的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the purchase of directors and officers liability insurance. It details the insurance plan, the approval process, and opinions from the supervisory board and independent directors. The document is relatively short (1460 characters) and does not contain financial statements or detailed financial data. It is an announcement of a corporate governance-related decision rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is not a voting result or a remuneration report. The closest fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-18 Chinese
2021年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) issued by a certified public accounting firm for the company 云南沃森生物技术股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and includes consolidated and parent company financial statements for the fiscal year ending December 31, 2021. The content is consistent with a standalone audit report rather than a full annual report or other filing types. The document length is substantial (15,000 characters), and it contains actual financial data and detailed audit procedures, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2021
2022-03-18 Chinese
关于2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan by the company Yunnan Watson Biotechnology Co., Ltd. It details the proposed cash dividend per share, the board of directors' and supervisory board's opinions, and the need for shareholder approval. The document is relatively short (1730 characters) and focuses on the dividend distribution proposal rather than the full financial report or detailed financial statements. It does not contain comprehensive financial data or full annual report content but rather announces the dividend plan and related approvals. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2022-03-18 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.